-
-
-
-
-
-
-
Crinetics Pharmaceuticals (CRNX) Tops Q1 EPS by 5c
-
-
-
-
-
-
-
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adren
-
-
-
-
-
-
-
Crinetics Pharmaceuticals (CRNX) Misses Q1 EPS by 11c
-
-
-
-
-
-
-
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
-
-
-
-
-
-
-
Crinetics Pharmaceuticals (CRNX) Misses Q4 EPS by 4c
-
-
-
-
-
-
-
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
1,217,586 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

